36. Epidermolysis bullosa Clinical trials / Disease details

Clinical trials : 163 / Drugs : 185 - (DrugBank : 46) / Drug target genes : 50 - Drug target pathways : 125

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05143190 (ClinicalTrials.gov)	December 2, 2021	9/11/2021	Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)	A Phase 2b Open-Label Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01 in Study PTR-01-002	Recessive Dystrophic Epidermolysis Bullosa	Drug: PTR-01	Phoenix Tissue Repair, Inc.	Phoenix Tissue Repair, a BridgeBio company	Completed	12 Years	N/A	All	2	Phase 2	United States
2	NCT04599881 (ClinicalTrials.gov)	October 15, 2020	8/10/2020	A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa	A Phase 2 Open-Label Study of PTR-01 in Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)	Recessive Dystrophic Epidermolysis Bullosa	Drug: PTR-01	Phoenix Tissue Repair, Inc.	NULL	Completed	12 Years	N/A	All	6	Phase 2	United States
3	NCT03752905 (ClinicalTrials.gov)	January 9, 2019	19/11/2018	A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)	A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)	Recessive Dystrophic Epidermolysis Bullosa	Drug: PTR-01;Drug: Normal saline	Phoenix Tissue Repair, Inc.	NULL	Completed	16 Years	N/A	All	12	Phase 1/Phase 2	United States